UBS Group
ACRS icon

UBS Group’s Aclaris Therapeutics ACRS Stock Holding History

UBS Group’s Portfolio ACRS Stock Details ACRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.36M Buy
257,001
+50,187
+24% +$224K ﹤0.01% 5459
2026
Q1 		$776K Sell
206,814
-155,724
-43% -$525K ﹤0.01% 5752
2025
Q4 		$1.09M Buy
362,538
+257,400
+245% +$650K ﹤0.01% 5486
2025
Q3 		$200K Sell
105,138
-48,034
-31% -$83.7K ﹤0.01% 6672
2025
Q2 		$218K Buy
153,172
+79,180
+107% +$107K ﹤0.01% 6663
2025
Q1 		$113K Buy
73,992
+4,529
+7% +$9.66K ﹤0.01% 6961
2024
Q4 		$172K Buy
69,463
+37,611
+118% +$93.6K ﹤0.01% 6543
2024
Q3 		$36.6K Sell
31,852
-1,939
-6% -$2.38K ﹤0.01% 7021
2024
Q2 		$37.2K Sell
33,791
-36,610
-52% -$43K ﹤0.01% 6912
2024
Q1 		$87.3K Buy
70,401
+50,777
+259% +$60.6K ﹤0.01% 6284
2023
Q4 		$20.6K Sell
19,624
-32,054
-62% -$97.8K ﹤0.01% 7088
2023
Q3 		$354K Buy
51,678
+48,864
+1,736% +$418K ﹤0.01% 4924
2023
Q2 		$29.2K Buy
2,814
+781
+38% +$7.07K ﹤0.01% 6729
2023
Q1 		$16.4K Sell
2,033
-373
-16% -$4.73K ﹤0.01% 7233
2022
Q4 		$37.9K Sell
2,406
-465
-16% -$7.48K ﹤0.01% 7018
2022
Q3 		$45K Buy
2,871
+465
+19% +$7.33K ﹤0.01% 6442
2022
Q2 		$34K Buy
2,406
+704
+41% +$9.87K ﹤0.01% 6242
2022
Q1 		$29K Sell
1,702
-44,486
-96% -$607K ﹤0.01% 7024
2021
Q4 		$671K Buy
46,188
+44,538
+2,699% +$675K ﹤0.01% 4739
2021
Q3 		$30K Sell
1,650
-1,249
-43% -$20K ﹤0.01% 6741
2021
Q2 		$51K Sell
2,899
-3,467
-54% -$78.8K ﹤0.01% 6405
2021
Q1 		$160K Buy
6,366
+5,060
+387% +$99K ﹤0.01% 5621
2020
Q4 		$8K Sell
1,306
-3,710
-74% -$15.7K ﹤0.01% 7606
2020
Q3 		$13K Buy
5,016
+4,469
+817% +$10K ﹤0.01% 6622
2020
Q2 		$1K Sell
547
-18,450
-97% -$24.7K ﹤0.01% 7728
2020
Q1 		$20K Sell
18,997
-18,809
-50% -$25.6K ﹤0.01% 6481
2019
Q4 		$71K Buy
37,806
+28,749
+317% +$47.6K ﹤0.01% 6172
2019
Q3 		$10K Sell
9,057
-907,495
-99% -$1.29M ﹤0.01% 7148
2019
Q2 		$2.01M Buy
916,552
+233,013
+34% +$1.27M ﹤0.01% 3148
2019
Q1 		$4.09M Sell
683,539
-633,721
-48% -$4.2M ﹤0.01% 2371
2018
Q4 		$9.73M Buy
1,317,260
+1,317,241
+6,932,847% +$13.6M ﹤0.01% 1594
2018
Q3 		$0 Hold
19
– – ﹤0.01% 7945
2018
Q2 		$0 Sell
19
-2,414
-99% -$44.6K ﹤0.01% 7938
2018
Q1 		$43K Sell
2,433
-260
-10% -$5.51K ﹤0.01% 5824
2017
Q4 		$66K Sell
2,693
-3,362
-56% -$81.9K ﹤0.01% 5630
2017
Q3 		$156K Buy
6,055
+2,768
+84% +$74.2K ﹤0.01% 5023
2017
Q2 		$90K Sell
3,287
-1,175
-26% -$31.9K ﹤0.01% 5235
2017
Q1 		$133K Buy
4,462
+1,681
+60% +$48.5K ﹤0.01% 4910
2016
Q4 		$75K Buy
2,781
+578
+26% +$14.7K ﹤0.01% 5496
2016
Q3 		$56K Buy
2,203
+1,262
+134% +$26.8K ﹤0.01% 5416
2016
Q2 		$17K Buy
941
+308
+49% +$6.1K ﹤0.01% 6410
2016
Q1 		$12K Buy
633
+524
+481% +$10K ﹤0.01% 6529
2015
Q4 		$3K Buy
+109
New +$2.12K ﹤0.01% 7858

Other funds holding ACRS

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $732M AUM 275.56% 1-Year Est. Return

UBS Group's ACRS Position: Q2 2026 in Review

UBS Group increased its Aclaris Therapeutics (ACRS) stake by 24% in Q2 2026, buying an estimated $224K and bringing the position to 257,001 shares worth $1.36M. The position accounts for ﹤0.01% of the portfolio, ranked #5459.

UBS Group first reported a position in ACRS in Q4 2015 and has held it in 43 quarters since. The position peaked at $9.73M in Q4 2018. 149 funds tracked by Wall St. Rank hold ACRS as of Q2 2026.

  • UBS Group held 257,001 shares of Aclaris Therapeutics worth $1.36M as of Q2 2026.
  • UBS Group bought 50,187 Aclaris Therapeutics shares in Q2 2026, an estimated $224K.
  • Aclaris Therapeutics made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #5459 holding.
  • UBS Group first reported a position in Aclaris Therapeutics in Q4 2015 and has held it in 43 quarters since.
  • UBS Group's Aclaris Therapeutics position peaked at $9.73M in Q4 2018.
  • 149 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.